44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Cancer & Metastasis Research

Sign up for email alert when new content gets added: Sign up

Testing the efficacy of vitamin D3 and metformin to retard the development of subcutaneous ehrlich ascites carcinomas in-vivo


August 5-6, 2019 | Singapore

Prashant kumar M V

JSS Medical College, India

ScientificTracks Abstracts: J Can Res Metastasis

Abstract :

Vitamin D3 and metformin are widely used in humans for regulating mineral metabolism and blood glucose levels, respectively. Interestingly these two agents have also shown to exhibit chemo preventive effects against various carcinoma cells in vitro and in vivo. But it is not known, whether combining these two anti-cancer agents helps in synergistic tumor growth inhibition. Therefore, in this study the potency of combining Vitamin-D3 and Metformin was investigated against EAC cells injected solid tumor model. Experimentally, EAC bearing mice were given Vitamin D3 (125μg/kg and 250μg/kg) and Metformin (125mg/kg and 250mg/kg) alone or in combination (VD3 125μg/kg + M 125mg/kg) in a simultaneous and sequentially treatment regimens and tumor weight recorded at the end of the experiment. Analysis of the data showed an about 52% and 59% growth inhibition with VD3 125μg/kg and 250μg/kg, respectively, whereas the administration of Metformin yielded 57% and 62% growth inhibition at 125mg/kg and 250mg/kg, respectively. Simultaneous administration of 125μg/kg VD3 and 125mg/kg Metformin reduced the tumor weight by 63% indicating a marginal increase in the treatment efficacy. However, no such increase in the efficacy was observed when these two drugs administered sequentially. Mechanistically, VD3 and Metformin inhibited the development of blood vessels and induced apoptosis in tumors. In conclusion, our data suggest simultaneous administration of VD3 and Metformin for treating cancers.

Biography :

Prashanth kumar M V is an Indian council of medical research (ICMR) Senior Research Fellow at Centre for excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education and Research (JSS- AHE&R), Mysuru. His work focuses on developing the combination therapies on anti-cancer agent for treating breast cancers by repurposing the existing drugs. He has identified Vitamin D3 and Anti-diabetic drug Metformin combination for breast cancer treatment in vitro and in vivo model. As a Principle Investigator he has received research fund from the home university for his excellence work on V-D3 and Metformin as anti-cancer agents on Breast cancer cell line. He has published his work in national and international reputed peer reviewed journals. He has Presented posters, delivered an oral talk as delegate speaker and received best oral presentation award in national and international conferences.

E-mail: [email protected]

Google Scholar citation report
Citations : 8

Journal of Cancer & Metastasis Research received 8 citations as per Google Scholar report